Taking care of people and the planet to preserve the future

With the aspiration of bringing curative drug therapies and visionary healthcare solutions to patients worldwide, Mr. Mauvernay is President of Après-demain SA, the parent company of Debiopharm, a Swiss, privately owned, biopharmaceutical company founded by his father over 40 years ago. Debiopharm, with 15 ongoing drug research programs, has developed two blockbuster therapies for cancer patients, oxaliplatin and triptorelin, along with a potential 3rd Head & Neck Cancer drug currently in phase III development with an international partner. Après-demain SA invests in a variety of industries including companies impacting sustainable energy, education, food, services to individuals with real estate, via 30+ direct investments in companies as well as LP investments in more than 100 funds globally. In addition, Mr. Mauvernay is also Chairman of the investment committee of Debiopharm Innovation Fund, backed by his experience as an entrepreneur in the international cosmetics industry before joining his family’s drug development business and asset diversification activities. His educational background includes a Master of Science in Economics and Marketing along with an MBA from the 'Institut d'Administration des Entreprises’.

Ms Calvayrac graduated from the University of Paris (Panthéon-Assas), where she obtained a "Diplôme d'Etudes Supérieures Spécialisées" in Business Law and Tax in 1988 (DESS, currently called "Master II Degree"). She then started a career in the banking sector during which she acquired a broad experience in various positions at Le Crédit Lyonnais (Crédit Agricole Group) in Marketing, Corporate Financing, Retail Banking and Human Resources, before becoming Director of the Financing Department for France, in charge of the Financing for Small Enterprises and of the Real Estate Financing for individuals. In 2008 she joined Après-demain SA Asset Management team as General Secretary and became Director in 2010. In 2020, she was appointed Senior Vice President of Après-demain SA Asset Management division, before becoming Asset Diversification Strategic Leader in 2023. Within the Après-demain Group, she has also been President of Impact Healthcare SA since 2022, and is a board member of various portfolio companies.

Ms Le Coz Sanchez obtained a Master’s degree at the University of Paris-La Sorbonne in 1998: DESS "Information and technical decisions in the company". She completed her training by becoming a CFA® charter holder. Ms Le Coz Sanchez previously worked in various large multinational companies where she was responsible for planning, forecasting and budgeting. She joined the capital management team of Après-demain SA in May 2010 as a financial analyst. Between 2012 and 2020, she led the Private Equity activities as part of the investment diversification strategy. She was a member of the board of directors for various portfolio companies and of certain fund advisory boards. In 2021, she was appointed General Secretary of the Capital Management division of Après-demain SA, then Vice President Capital Management in 2023.